Art
J-GLOBAL ID:201802229709945857   Reference number:18A2141046

Central Nervous System Lymphoma Harboring the JAK2 V617F Mutation That Developed after a 20-year History of Polycythemia Vera

20年来続いている真性多血症後に発症したJAK2 V617F変異陽性の中枢神経系リンパ腫
Author (11):
Material:
Volume: 57  Issue: 22  Page: 3293-3297(J-STAGE)  Publication year: 2018 
JST Material Number: U0033A  ISSN: 1349-7235  Document type: Article
Article type: 原著論文  Country of issue: Japan (JPN)  Language: ENGLISH (EN)
Thesaurus term:
Thesaurus term/Semi thesaurus term
Keywords indexed to the article.
All keywords is available on JDreamIII(charged).
On J-GLOBAL, this item will be available after more than half a year after the record posted. In addtion, medical articles require to login to MyJ-GLOBAL.
,...
Semi thesaurus term:
Thesaurus term/Semi thesaurus term
Keywords indexed to the article.
All keywords is available on JDreamIII(charged).
On J-GLOBAL, this item will be available after more than half a year after the record posted. In addtion, medical articles require to login to MyJ-GLOBAL.
,...
   To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=18A2141046&from=J-GLOBAL&jstjournalNo=U0033A") }}
JST classification (3):
JST classification
Category name(code) classified by JST.
Clinical oncology in general  ,  Blood cell tumors(=neoplasms)  ,  Nervous system diseases 
Reference (21):
  • 1. Baxter EJ, Scott LM, Campbell PJ, et al; Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365: 1054-1061, 2005.
  • 2. James C, Ugo V, Le Couédic JP, et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera. Nature 434: 1144-1148, 2005.
  • 3. Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106: 2162-2168, 2005.
  • 4. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352: 1779-1790, 2005.
  • 5. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7: 387-397, 2005.
more...

Return to Previous Page